Comparison 2. Heparin versus pentasaccharide.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Venous thromboembolism	1	175	Risk Ratio (M‐H, Fixed, 95% CI)	0.83 [0.19, 3.61]
2.2 Major bleeding	1	198	Risk Ratio (M‐H, Fixed, 95% CI)	1.70 [0.42, 6.92]
2.3 All‐cause mortality	1	198	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
2.4 Venous thromboembolism‐related mortality	1	198	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
2.5 Pulmonary embolism	1	198	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
2.6 Deep vein thrombosis	1	175	Risk Ratio (M‐H, Fixed, 95% CI)	0.83 [0.19, 3.61]
2.7 Adverse events (thrombocytopaenia)	1	198	Risk Ratio (M‐H, Fixed, 95% CI)	0.34 [0.01, 8.25]
2.8 Adverse events (atrial fibrillation)	1	198	Risk Ratio (M‐H, Fixed, 95% CI)	2.04 [0.19, 22.14]
2.9 Adverse events (rash)	1	198	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.06, 16.09]
2.10 Adverse events (nausea and vomiting)	1	198	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.15, 7.10]